title: Reply to Vincenza Conteduca, Cristian Lolli, and Ugo De Giorgi's Letter to the Editor re: Pasquale Rescigno, David Lorente, Diletta Bianchini, et al. Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016;70:724-31.
authors.affiliation: The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK.
authors.forename: Pasquale
authors.initials: P
authors.lastname: Rescigno
authors.affiliation: The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, UK. Electronic address: johann.de-bono@icr.ac.uk.
authors.forename: Johann S
authors.initials: JS
authors.lastname: de Bono
mesh_terms: D000069501:Abiraterone Acetate; D000736:Androstenes; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen; D064129:Prostatic Neoplasms, Castration-Resistant; D043823:Taxoids
chemical_list: D000736:Androstenes; D043823:Taxoids; D017430:Prostate-Specific Antigen; D000069501:Abiraterone Acetate